SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 252-256

  Uckun, F M ^a   Mao, C ^a   Jan, S T ^a   Huang, H ^a   Vassilev, A O ^a   Sudbeck, E A ^a   Navara, C S ^a   Narla, R K ^a  

^a Parker Hughes Cancer Center   (United States)

Author keywords

Anticancer agent; C jun; C Jun N terminal kinase; Microtubules; Tubulin modulators

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; COBRA 0; COBRA 1; MICROTUBULE PROTEIN; PYRAN DERIVATIVE; SPONGISTATIN 1; STRESS ACTIVATED PROTEIN KINASE; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRAIN TUMOR; BREAST CANCER; CANCER CELL; DRUG BINDING; GLIOBLASTOMA; HUMAN; MICROTUBULE; MITOSIS; MODULATION; MOLECULAR MODEL; NONHUMAN; POLYMERIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; FURANS; HUMANS; NEOPLASMS; PYRANS; SPIRO COMPOUNDS;

EID: 0033755284     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Microtubule functions
2. Pharmacological probes of microtubule function
3. The role of nucleation in patterning microtubule networks
4. Tubulin and microtubule structure
5. A model of the microtubule-kinesin complex based on electron cryomicroscopy and X-ray crystallography
6. Structure of the αβ tubulin dimer by electron crystallography
7. FtsZ, a prolaryotic homolog of tubulin?
8. The binding of vincristine, vinblastine and colchicine to tubulin
9. Promotion of microtubule assembly in vitro by taxol
10. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
11. Interaction of estramustine phosphate with microtubule-associated proteins
12. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
13. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin
14. The spongistatins potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain
15. Stereocontrolled synthesis of a novel pharmacophore of the tubulin-depolymerizing marine natural product spongistatin
16. Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1
17. Phase I pharmacologic study of a new Vinca alkaloid: Navelbine
18. Interaction of cryptophycin 1 with tubulin and microtubules
19. Studies on macrocyclic lactone antibiotics. XI Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues
20. Antimitotic activity of the potent tumor inhibitor maytansine
21. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain
22. A rationally designed anti-cancer drug targeting a unique binding cavity of tubulin
23. Stereoselective synthesis of a versatile intermediate for the total synthesis of mono- and bis-THF containing annonaceous acetogenins
24. Isolation and structure of spongistatin 1
25. High-resolution model of the microtubule
26. Microtubule polymerization dynamics
27. Low potency of taxol at microtubule minus ends: Implications for its antimitotic and therapeutic mechanism
28. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
29. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents
30. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
31. Taxol differentially modulates the dynamics of microbules assembled from unfractionated and purified beta-tubulin isotypes
32. 3-(Iodoacetamido)-benzoylurea: A Novel cancericidal tubulin ligand that inhibitis microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells
33. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimenthoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154)
34. Role of tyrosine phosphorylation in radiation-induced activation of c-jun protooncogene in human lymphohematopoietic precursor cells
35. AP-1 function and regulation
36. Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells
37. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways
38. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells
39. Differential regulation of mitogen-activate protein kinases by microtubule-binding agents in human breast cancer cells
40. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK)
41. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
42. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M
43. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells
44. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's Tyrosine Kinase (BTK): LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]
45. α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl]pro-penamide: An inhibitor of the EGF receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells
46. Bruton's tyrosine kinae as an inhibitor of the Fas/CD95 death-inducing signaling complex
47. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents
48. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
49. Anticancer drugs induce caspase-8/FLICE actication and apoptosis in the absence of CD95 receptor/ligand interaction
50. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
51. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells